Click here to get full coverage on Janux Therapeutics, Inc. (JANX) faces platform risk amid lack of durability data on JANX007 - MSN

Janux Therapeutics, Inc. (JANX) faces platform risk amid lack of durability data on JANX007  MSN

Janux Therapeutics, Inc. (JANX) faces platform risk amid lack of durability data on JANX007 - MSN

Click here to get full coverage on Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by Brokerages  MarketBeat

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Click here to get full coverage on JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Zacks Investment Research

JANX Enters Global Oncology Collaboration With BMY, Stock Rises  Zacks Investment Research

JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Zacks Investment Research

Click here to get full coverage on Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - Business Wire

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors  Business Wire

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - Business Wire

Click here to get full coverage on $JANX stock is down 46% today. Here's what we see in our data. - Quiver Quantitative

$JANX stock is down 46% today. Here's what we see in our data.  Quiver Quantitative

$JANX stock is down 46% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Janux Therapeutics Repeat Insider Selling Not A Positive Indicator - simplywall.st

Janux Therapeutics Repeat Insider Selling Not A Positive Indicator  simplywall.st

Janux Therapeutics Repeat Insider Selling Not A Positive Indicator - simplywall.st

Click here to get full coverage on Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX) - Yahoo Finance

Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX)  Yahoo Finance

Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX) - Yahoo Finance

Click here to get full coverage on Bristol Myers inks licensing deal with Janux for cancer therapy - Seeking Alpha

Bristol Myers inks licensing deal with Janux for cancer therapy  Seeking Alpha

Bristol Myers inks licensing deal with Janux for cancer therapy - Seeking Alpha

Click here to get full coverage on Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - Business Wire

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer  Business Wire

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - Business Wire

Click here to get full coverage on Why Janux Therapeutics (JANX) Draws Analyst Optimism Despite Widening Year-to-Date Losses - Yahoo Finance

Why Janux Therapeutics (JANX) Draws Analyst Optimism Despite Widening Year-to-Date Losses  Yahoo Finance

Why Janux Therapeutics (JANX) Draws Analyst Optimism Despite Widening Year-to-Date Losses - Yahoo Finance

Click here to get full coverage on Janux Therapeutics (JANX) Is Down 50.7% After Positive JANX007 Phase 1 mCRPC Update - What's Changed - simplywall.st

Janux Therapeutics (JANX) Is Down 50.7% After Positive JANX007 Phase 1 mCRPC Update - What's Changed  simplywall.st

Janux Therapeutics (JANX) Is Down 50.7% After Positive JANX007 Phase 1 mCRPC Update - What's Changed - simplywall.st

Click here to get full coverage on Janux Therapeutics (JANX): Valuation Check After Positive JANX007 Phase 1 Data and Sharp Share Price Drop - Yahoo Finance

Janux Therapeutics (JANX): Valuation Check After Positive JANX007 Phase 1 Data and Sharp Share Price Drop  Yahoo Finance

Janux Therapeutics (JANX): Valuation Check After Positive JANX007 Phase 1 Data and Sharp Share Price Drop - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $JANX Given $12 Price Target - Quiver Quantitative

New Analyst Forecast: $JANX Given $12 Price Target  Quiver Quantitative

New Analyst Forecast: $JANX Given $12 Price Target - Quiver Quantitative

Click here to get full coverage on Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates  Yahoo Finance

Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program - Yahoo Finance

Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program  Yahoo Finance

Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program - Yahoo Finance

Click here to get full coverage on Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo Finance

Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains?  Yahoo Finance

Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo Finance

Click here to get full coverage on Price-Driven Insight from (JANX) for Rule-Based Strategy - Stock Traders Daily

Price-Driven Insight from (JANX) for Rule-Based Strategy  Stock Traders Daily

Price-Driven Insight from (JANX) for Rule-Based Strategy - Stock Traders Daily

Click here to get full coverage on Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT - Yahoo Finance

Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT  Yahoo Finance

Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT - Yahoo Finance

Click here to get full coverage on Janux Therapeutics (JANX) Gets Initiated With a Buy Rating at Truist Financial - Yahoo Finance

Janux Therapeutics (JANX) Gets Initiated With a Buy Rating at Truist Financial  Yahoo Finance

Janux Therapeutics (JANX) Gets Initiated With a Buy Rating at Truist Financial - Yahoo Finance

Click here to get full coverage on Reassessing Janux Therapeutics (JANX) Valuation After Mixed Market Reaction to New JANX007 Phase 1 Data - simplywall.st

Reassessing Janux Therapeutics (JANX) Valuation After Mixed Market Reaction to New JANX007 Phase 1 Data  simplywall.st

Reassessing Janux Therapeutics (JANX) Valuation After Mixed Market Reaction to New JANX007 Phase 1 Data - simplywall.st

Click here to get full coverage on Stifel Maintains Janux Therapeutics (JANX) Buy Recommendation - Nasdaq

Stifel Maintains Janux Therapeutics (JANX) Buy Recommendation  Nasdaq

Stifel Maintains Janux Therapeutics (JANX) Buy Recommendation - Nasdaq

Click here to get full coverage on Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million  Benzinga

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga

Click here to get full coverage on Janux Therapeutics: Downgrading To 'Hold' Rating After Latest Updated Phase 1 JANX007 mCRPC Data - Seeking Alpha

Janux Therapeutics: Downgrading To 'Hold' Rating After Latest Updated Phase 1 JANX007 mCRPC Data  Seeking Alpha

Janux Therapeutics: Downgrading To 'Hold' Rating After Latest Updated Phase 1 JANX007 mCRPC Data - Seeking Alpha

Click here to get full coverage on Janux Therapeutics (NASDAQ:JANX) Shares Gap Down - Should You Sell? - MarketBeat

Janux Therapeutics (NASDAQ:JANX) Shares Gap Down - Should You Sell?  MarketBeat

Janux Therapeutics (NASDAQ:JANX) Shares Gap Down - Should You Sell? - MarketBeat

Click here to get full coverage on Why Janux Therapeutics (JANX) Is Up 10.5% After Pipeline Progress Fuels Optimism for Prostate Cancer Therapies - Yahoo Finance

Why Janux Therapeutics (JANX) Is Up 10.5% After Pipeline Progress Fuels Optimism for Prostate Cancer Therapies  Yahoo Finance

Why Janux Therapeutics (JANX) Is Up 10.5% After Pipeline Progress Fuels Optimism for Prostate Cancer Therapies - Yahoo Finance

Click here to get full coverage on With Janux Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis

With Janux Therapeutics Stock Sliding, Have You Assessed The Risk?  Trefis

With Janux Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis

Click here to get full coverage on Janux stock a new Buy at Truist on H2 catalysts (JANX:NASDAQ) - Seeking Alpha

Janux stock a new Buy at Truist on H2 catalysts (JANX:NASDAQ)  Seeking Alpha

Janux stock a new Buy at Truist on H2 catalysts (JANX:NASDAQ) - Seeking Alpha

Click here to get full coverage on Insider Sale: Chief Business Officer of $JANX Sells 16,665 Shares - Quiver Quantitative

Insider Sale: Chief Business Officer of $JANX Sells 16,665 Shares  Quiver Quantitative

Insider Sale: Chief Business Officer of $JANX Sells 16,665 Shares - Quiver Quantitative

Click here to get full coverage on JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target - Yahoo Finance

JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target  Yahoo Finance

JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target - Yahoo Finance

Click here to get full coverage on (JANX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

(JANX) Price Dynamics and Execution-Aware Positioning  Stock Traders Daily

(JANX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Click here to get full coverage on JANX December 2026 Options Begin Trading - Nasdaq

JANX December 2026 Options Begin Trading  Nasdaq

JANX December 2026 Options Begin Trading - Nasdaq

Click here to get full coverage on Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - MarketBeat

Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update  MarketBeat

Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - MarketBeat

Click here to get full coverage on New Analyst Forecast: $JANX Given $70.0 Price Target - Quiver Quantitative

New Analyst Forecast: $JANX Given $70.0 Price Target  Quiver Quantitative

New Analyst Forecast: $JANX Given $70.0 Price Target - Quiver Quantitative

Click here to get full coverage on Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans - simplywall.st

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans  simplywall.st

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans - simplywall.st

Click here to get full coverage on Janux Therapeutics (JANX) Moves 8.8% Higher: Will This Strength Last? - Nasdaq

Janux Therapeutics (JANX) Moves 8.8% Higher: Will This Strength Last?  Nasdaq

Janux Therapeutics (JANX) Moves 8.8% Higher: Will This Strength Last? - Nasdaq

Click here to get full coverage on Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Yahoo Finance

Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?  Yahoo Finance

Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Yahoo Finance

Click here to get full coverage on Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters

Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug  Reuters

Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters

Click here to get full coverage on Janux Therapeutics: The Rumor Mill Spins Up Again (NASDAQ:JANX) - Seeking Alpha

Janux Therapeutics: The Rumor Mill Spins Up Again (NASDAQ:JANX)  Seeking Alpha

Janux Therapeutics: The Rumor Mill Spins Up Again (NASDAQ:JANX) - Seeking Alpha

Click here to get full coverage on Morning Market Movers: TAOP, JANX, MDB, ABTC See Big Swings - RTTNews

Morning Market Movers: TAOP, JANX, MDB, ABTC See Big Swings  RTTNews

Morning Market Movers: TAOP, JANX, MDB, ABTC See Big Swings - RTTNews

Click here to get full coverage on Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC - Business Wire

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC  Business Wire

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC - Business Wire

Click here to get full coverage on BTIG Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100 - 富途牛牛

BTIG Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100  富途牛牛

BTIG Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100 - 富途牛牛

Click here to get full coverage on Piper Sandler Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $30 - 富途牛牛

Piper Sandler Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $30  富途牛牛

Piper Sandler Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $30 - 富途牛牛

Click here to get full coverage on JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛

JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $50  富途牛牛

JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛

Click here to get full coverage on Janux Therapeutics Signs Exclusive License and Collaboration Agreement With Bristol-Myers Squibb - TradingView

Janux Therapeutics Signs Exclusive License and Collaboration Agreement With Bristol-Myers Squibb  TradingView

Janux Therapeutics Signs Exclusive License and Collaboration Agreement With Bristol-Myers Squibb - TradingView

Click here to get full coverage on Janux Falls Back To Earth As 'Best-In-Class' Hopes Confront Phase 1 Reality (Rating Downgrade) - Seeking Alpha

Janux Falls Back To Earth As 'Best-In-Class' Hopes Confront Phase 1 Reality (Rating Downgrade)  Seeking Alpha

Janux Falls Back To Earth As 'Best-In-Class' Hopes Confront Phase 1 Reality (Rating Downgrade) - Seeking Alpha

Click here to get full coverage on Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - Chartmill

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors  Chartmill

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - Chartmill

Click here to get full coverage on Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - Business Wire

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study  Business Wire

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - Business Wire

Click here to get full coverage on Wolfe Research Initiates Coverage of Janux Therapeutics (JANX) with Peer Perform Recommendation - Nasdaq

Wolfe Research Initiates Coverage of Janux Therapeutics (JANX) with Peer Perform Recommendation  Nasdaq

Wolfe Research Initiates Coverage of Janux Therapeutics (JANX) with Peer Perform Recommendation - Nasdaq

Click here to get full coverage on Janux reports positive phase 1 results for JANX007 in mCRPC; stock down (JANX:NASDAQ) - Seeking Alpha

Janux reports positive phase 1 results for JANX007 in mCRPC; stock down (JANX:NASDAQ)  Seeking Alpha

Janux reports positive phase 1 results for JANX007 in mCRPC; stock down (JANX:NASDAQ) - Seeking Alpha

Click here to get full coverage on Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound - Stocktwits

Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound  Stocktwits

Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound - Stocktwits

Click here to get full coverage on How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing - Stock Traders Daily

How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing  Stock Traders Daily

How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing - Stock Traders Daily

Click here to get full coverage on Janux Therapeutics (NASDAQ:JANX) Sets New 12-Month Low - What's Next? - MarketBeat

Janux Therapeutics (NASDAQ:JANX) Sets New 12-Month Low - What's Next?  MarketBeat

Janux Therapeutics (NASDAQ:JANX) Sets New 12-Month Low - What's Next? - MarketBeat

Click here to get full coverage on Can Janux Therapeutics' Upcoming Immunotherapy Updates Drive A Stock Rebound? - RTTNews

Can Janux Therapeutics' Upcoming Immunotherapy Updates Drive A Stock Rebound?  RTTNews

Can Janux Therapeutics' Upcoming Immunotherapy Updates Drive A Stock Rebound? - RTTNews

Click here to get full coverage on Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring the 245% Upside Potential in Biotech - DirectorsTalk Interviews

Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring the 245% Upside Potential in Biotech  DirectorsTalk Interviews

Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring the 245% Upside Potential in Biotech - DirectorsTalk Interviews

Click here to get full coverage on Janux Therapeutics Craters 53% On Prostate Cancer Update; Is It An 'Overreaction'? - Investor's Business Daily

Janux Therapeutics Craters 53% On Prostate Cancer Update; Is It An 'Overreaction'?  Investor's Business Daily

Janux Therapeutics Craters 53% On Prostate Cancer Update; Is It An 'Overreaction'? - Investor's Business Daily

Click here to get full coverage on Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC - Business Wire

Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC  Business Wire

Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC - Business Wire

Click here to get full coverage on Barclays Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail

Barclays Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)  The Globe and Mail

Barclays Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail

Click here to get full coverage on Janux shares halve despite still strong Phase I data - BioCentury

Janux shares halve despite still strong Phase I data  BioCentury

Janux shares halve despite still strong Phase I data - BioCentury

Click here to get full coverage on Janux Therapeutics (JANX) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union

Janux Therapeutics (JANX) Stock Price Prediction: Today, Tomorrow, Next Week  Traders Union

Janux Therapeutics (JANX) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union

Click here to get full coverage on Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits

Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb  Stocktwits

Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits

Click here to get full coverage on Bank of America Securities Keeps Their Buy Rating on Janux Therapeutics Inc (JANX) - The Globe and Mail

Bank of America Securities Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)  The Globe and Mail

Bank of America Securities Keeps Their Buy Rating on Janux Therapeutics Inc (JANX) - The Globe and Mail

Click here to get full coverage on Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration - Yahoo Finance

Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration  Yahoo Finance

Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration - Yahoo Finance

Click here to get full coverage on Options Exercise: Janux Executive Sells 16,665 Shares for $501,000 - The Motley Fool

Options Exercise: Janux Executive Sells 16,665 Shares for $501,000  The Motley Fool

Options Exercise: Janux Executive Sells 16,665 Shares for $501,000 - The Motley Fool

Click here to get full coverage on Janux Therapeutics, Inc. (JANX) Stock Analysis: A 362% Potential Upside Beckons Investors - DirectorsTalk Interviews

Janux Therapeutics, Inc. (JANX) Stock Analysis: A 362% Potential Upside Beckons Investors  DirectorsTalk Interviews

Janux Therapeutics, Inc. (JANX) Stock Analysis: A 362% Potential Upside Beckons Investors - DirectorsTalk Interviews

Click here to get full coverage on Janux Therapeutics, Inc. (JANX) Stock Analysis: A Biotech With A Potential 185% Upside - DirectorsTalk Interviews

Janux Therapeutics, Inc. (JANX) Stock Analysis: A Biotech With A Potential 185% Upside  DirectorsTalk Interviews

Janux Therapeutics, Inc. (JANX) Stock Analysis: A Biotech With A Potential 185% Upside - DirectorsTalk Interviews

Click here to get full coverage on Janux Therapeutics: What's My Inflection Point? (NASDAQ:JANX) - Seeking Alpha

Janux Therapeutics: What's My Inflection Point? (NASDAQ:JANX)  Seeking Alpha

Janux Therapeutics: What's My Inflection Point? (NASDAQ:JANX) - Seeking Alpha

Click here to get full coverage on Truist Securities reiterates Buy rating on Janux Therapeutics stock - Investing.com

Truist Securities reiterates Buy rating on Janux Therapeutics stock  Investing.com

JANX

Price Chart

Key Statistics

Technicals

About JANX

Latest News

Janux Therapeutics, Inc. (JANX) faces platform risk amid lack of durability data on JANX007 - MSN

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Zacks Investment Research

Advanced Charts

Top Gainers

Top Losers